Abstract:Background: The multidose Sabin-strain inactivated poliovirus vaccine (sIPV) has the potential to significantly aid in the eradication of poliomyelitis, particularly in low- and middle-income countries. As part of a phase III clinical trial in which infants were given three doses of primary immunization at 2, 3, and 4 months of age, this study aimed to evaluate immune persistence following primary immunization, as well as the safety and immunogenicity of a booster of the 5-dose sIPV in infants aged 18 months. Methods: Infants aged 18 months were given one booster dose of 5-dose sIPV in stage one, which was open-label. Unblinding was performed for stage two after completing primary immunization, which was randomized, blinded, and controlled; infants aged 18 months in the test group I–III, IPV group, and single-dose sIPV group were given one booster dose of 5-dose sIPV, conventional IPV, and single-dose sIPV, respectively, in stage two. Results: This study included 1438 infants in the immune persistence and safety set and 1387 infants in the booster per-protocol set. Fourteen months after primary immunization, the seropositivity rates (≥1:8) for types 1–3 were 100%, 99.88%, and 99.53% in the 5-dose sIPV groups; 100%, 98.97%, and 97.23% in the IPV group; and 99.66%, 100%, and 99.66% in the single-dose sIPV group. A total of 30 days after booster immunization, the seropositivity rates (≥1:8) of 3 serotypes in all the groups reached 100%. The geometric mean titers of neutralizing antibodies for types 1–3 in the 5-dose sIPV group were 9962.89, 10273, and 7870.21, with geometric mean increases of 15.76, 33.15, and 24.5, compared to the pre-booster level. The overall incidence of adverse reactions was 8.97%, with fever being the most common, observed at rates of 7.1%, 5.52%, and 7.96% in the 5-dose sIPV, IPV, and single-dose groups, respectively (p = 0.4845). Conclusions: The 5-dose sIPV has shown promising immune persistence and robust immune response following a booster immunization, coupled with an acceptable safety profile.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve include: 1. **Evaluation of immune persistence**: The study aims to evaluate the immune persistence of multi - dose Sabin - strain inactivated poliovirus vaccine (sIPV) in 18 - month - old infants after the basic immunization (i.e., the initial three - dose vaccination). Specifically, the researchers are concerned about whether the antibody levels induced by the vaccine can remain at the protective level continuously within 14 months after the initial immunization. 2. **Evaluation of the safety and immunogenicity of booster immunization**: The study also aims to evaluate the safety and immunogenicity of multi - dose sIPV after a booster dose is given at 18 months. This includes evaluating the increase in antibody levels after booster immunization and whether any adverse reactions occur. ### Specific research questions - **Immune persistence**: What are the seropositivity rates (SPRs) and geometric mean titers (GMTs) of neutralizing antibodies against the three serotypes (type 1, 2, and 3) of poliovirus in different vaccine groups (5 - dose sIPV, conventional IPV, and single - dose sIPV) within 14 months after the initial immunization? - **Immunogenicity after booster immunization**: What are the seropositivity rates, seroconversion rates (SCRs), geometric mean titers of neutralizing antibodies and their growth multiples (GMIs) against the three serotypes in different vaccine groups within 30 days after booster immunization? - **Safety**: What are the incidences of adverse reactions (ARs) in each vaccine group after the initial immunization and booster immunization? In particular, what are the incidences and severities of common adverse reactions such as fever? Through the research of these questions, the author hopes to provide a scientific basis for the further application of multi - dose Sabin - strain inactivated poliovirus vaccine (sIPV) and verify its effectiveness and safety in actual use. ### Research background Poliomyelitis (polio) is an acute infectious disease caused by the poliovirus, which mainly affects children, especially those under 5 years old. Although the Global Polio Eradication Initiative (GPEI) has made significant progress since its launch in 1988, there are still challenges in completely eradicating this disease. Therefore, the development of safe and effective vaccines is crucial for maintaining a polio - free state. The multi - dose Sabin - strain inactivated poliovirus vaccine (sIPV) studied in this paper aims to improve the accessibility and economy of the vaccine, especially in low - income and middle - income countries. ### Conclusion The study shows that 5 - dose sIPV exhibits good immune persistence after the initial immunization, and can significantly increase the antibody levels after booster immunization, with strong immunogenicity. In addition, the vaccine has good safety, with a low incidence of adverse reactions and most of them are mild. These results provide strong support for the wide application of this vaccine.

Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months

Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China

Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months

Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18–24 Months: A phase IV clinical trial

Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study

Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population

Quantitative Analysis of the Instant and Persistent Inhibition Effects of Maternal Poliovirus Antibodies on the Immune Response in a Phase IV Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine

Immunogenicity of Two Different Sequential Schedules of Inactivated Polio Vaccine Followed by Oral Polio Vaccine Versus Oral Polio Vaccine Alone in Healthy Infants in China

Immune persistence after different polio sequential immunization schedules in Chinese infants

Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses

Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination

Immuno-persistence after the fourth and fifth doses of inactivated polio vaccines in school-aged children

Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines

Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants

Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial

Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China

The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India

Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine

Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance